Rezūm water vapor thermal therapy in the treatment of benign prostatic hyperplasia: clinical outcomes and efficacy
Abstract
Relevance. Benign prostatic hyperplasia is one of the most common urological conditions in elderly men, with both its prevalence and symptom severity increasing proportionally with age. At the same time, the effectiveness of conservative therapy is often limited, as many patients continue to experience significant lower urinary tract symptoms despite medical treatment. The standard surgical option — transurethral resection of the prostate— is associated with risks such as bleeding, hospitalization, and a high incidence of sexual dysfunction, with retrograde ejaculation occurring in 50–70% of patients. In this context, water vapor thermal therapy (Rezūm) represents a promising minimally invasive alternative. It provides durable relief of BPH-related symptoms with minimal invasiveness, allowing patients to avoid long-term pharmacotherapy and reduce the risk of surgical complications, while preserving the prostate gland and sexual function.
Aim. To evaluate the early clinical outcomes and safety of Rezūm water vapor thermal therapy in patients with benign prostatic hyperplasia.
Materials and Methods. A retrospective single-center analysis was conducted on the treatment outcomes of 9 men (aged 49–78 years; mean age 59.4 ± 9.1 years) presenting with severe lower urinary tract symptoms (IPSS ≥ 22) and moderate prostate enlargement (30.8–70.0 mL). All patients underwent Rezūm thermal ablation (4–6 vapor injections; mean procedure duration 7.8 ± 1.5 minutes). Follow-up at 3 months…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.